Bexlosteride

Bexlosteride is a potent and noncompetitive inhibitor of the enzyme 5α-reductase related to finasteride and dutasteride.[1][2] It is selective for the type I isoform of the enzyme.[1] It advanced to Phase III clinical trials, but development was halted at that stage, and it was never marketed.[3][4]

Bexlosteride
Clinical data
Other namesLY 300502
Routes of
administration		Oral
ATC code
  • none
Legal status
Legal status
  • In general: uncontrolled
Identifiers
IUPAC name
  • (4aR,10bR)-8-Chloro-4-methyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC14H16ClNO
Molar mass249.74 g·mol−1
3D model (JSmol)
SMILES
  • CN1[C@@H]2CCc3cc(ccc3[C@H]2CCC1=O)Cl
InChI
  • InChI=1S/C14H16ClNO/c1-16-13-6-2-9-8-10(15)3-4-11(9)12(13)5-7-14(16)17/h3-4,8,12-13H,2,5-7H2,1H3/t12-,13-/m1/s1 Y
  • Key:WQBIOEFDDDEARX-CHWSQXEVSA-N Y
 NY (what is this?)  (verify)

See also

References
  1. Chang C (2002). Androgens and androgen receptor : mechanisms, functions, and clinical application. Boston: Kluwer Academic Publishers. ISBN 1-4020-7188-4.
  2. Lednicer D (2008). Strategies for Organic Drug Synthesis and Design. New York: Wiley-Interscience. ISBN 978-0-470-19039-5.
  3. "Drug Profile: Bexlosteride". Adis Insight.
  4. Reaxys entry for bexlosteride: Reaxys Registry Number: 6635310
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.